Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases
The DOI matches its Crossref record.
Abstract
BACKGROUND: Basal cell carcinoma (BCC) is the most common cancer in humans. Medical treatment modalities offer cost reductions and clinical advantages in selected cases such as low-risk areas, surgically inaccessible sites, patients with multiple neoplasms, and older, infirm or anticoagulated subjects. Tazarotene has been proposed for the treatment of BCC; however, data on its efficacy are lacking. OBJECTIVES: To investigate the efficacy of tazarotene in a large series of BCCs, better to define the clinical advantages and the mechanisms of action in vivo. METHODS: Tazarotene 0.1% gel was applied daily for 24 weeks to 154 small superficial and nodular BBCs. Clinicopathological changes were followed during the therapy by dermoscopic and histological examination. Proliferation, retinoic acid receptors and apoptosis were investigated by immunohistochemistry and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-biotin nick-end labelling on biopsies. RESULTS: At 24 weeks of therapy, 70.8% of the BCCs showed > 50% clinical and dermoscopic regression, and 30.5% healed without recurrences after 3 years of follow-up. At 12 weeks, biopsies showed that regression was associated with reduced proliferation and increased apoptosis of basaliomatous cells. Most unresponsive tumours displayed a keratotic differentiation. CONCLUSIONS: Tazarotene was effective in the majority of superficial and nodular undifferentiated BCCs treated, possibly by antiproliferative and proapoptotic actions in vivo. Keratotic BCCs were the major type among the unresponsive tumours, and were characterized by overexpression of p53 and cellular retinol binding protein-1 in comparison with undifferentiated tumours. Topical tazarotene represents an alternative medical choice for selected cases of BCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Basal cell carcinomas: attack of the hedgehog
Epstein, E. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2503 · Cited by 834
RAR and RXR modulation in cancer and metabolic disease
Altucci, L., Leibowitz, M. D., Ogilvie, K. M., de Lera, A. R., & Gronemeyer, H. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2397 · Cited by 517
Dermoscopy in General Dermatology
Zalaudek, I., Argenziano, G., Di Stefani, A., Ferrara, G., Marghoob, A. A., Hofmann-Wellenhof, R., Soyer, H. P., Braun, R., & Kerl, H. (2006) · Dermatology · doi:10.1159/000089015 · Cited by 252
Khalil, S., Bardawil, T., Stephan, C., Darwiche, N., Abbas, O., Kibbi, A. G., Nemer, G., & Kurban, M. (2017) · Journal of Dermatological Treatment · doi:10.1080/09546634.2017.1309349 · Cited by 217
“In one study, 0.1% tazarotene gel was applied daily to 154 small superficial and nodular BBCs (89).”
BackgroundMethodInfluential
Metadata
- Authors
- Bianchi, L., Orlandi, A., Campione, E., Angeloni, C., Costanzo, A., Spagnoli, L. G., & Chimenti, S.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07
- Volume
- 151
- Issue
- 1
- Pages
- 148-156
- ISSN
- 0007-0963 (ISSN-L)
- 1365-2133
- OpenAlex
- W1965500674
- Cited by
- 73
- References
- 0
- FWCI
- 2.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. https://app.cochat.ai/papers/10.1111/j.1365-2133.2004.06044.x
- The paper
- Bianchi, L., Orlandi, A., Campione, E., Angeloni, C., Costanzo, A., Spagnoli, L. G., & Chimenti, S. (2004). Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. British Journal of Dermatology. https://doi.org/10.1111/j.1365-2133.2004.06044.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.